Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
University of Pittsburgh
National Cancer Institute (NCI)
Travera Inc
Eastern Cooperative Oncology Group
Fondazione del Piemonte per l'Oncologia
Kaiser Permanente
Washington University School of Medicine
Arvinas Inc.
City of Hope Medical Center